Today is 31st October and it is Halloween.
MD2 and I were taking about the shape of Science and sometimes it feels like we are fighting against some giant Zombie Army, who “can’t see the wood for the trees”
You destroy the mindless naysayer only to be confronted by another and another and another. You can destroy them in so many ways but they keep on coming and coming.
If you get tired of the carnage then there is a risk that you become a Zombie yourself and end up surrounded by Zombies in either case, hoping for the day when the death ray wipes them off the face of the Earth.
However deep down you know Science Zombie Apocalypse II is coming soon.
I somethimes wonder if we do not make enough strides forward because we have become constrained by our thought and reporting process and the way we reward innovation. We accept that things are unknown because we told this by opinon leaders, when reading and abit of thought can tell you otherwise.
A string of unrelated facts and half-facts does not infrom, unless we can put them together to make a coherent story that reflects the real world and explains the known biologyi. Importantly we will not hear the voice that says “It’s behind you” as we turn into a Zombies and follow the pack.
The human experiment is the ultimate experiment. What can it tell us? Will looking in the haystack give us the needle, that we know is there? Or will it show us that our immune system fight infections on a regular basis?
Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Lünemann JD, Ruck T, Muraro PA, Bar’Or A, Wiendl H. Nat Rev Neurol. 2019 Oct 24. doi: 10.1038/s41582-019-0268-z. [Epub ahead of print]
New so-called immune reconstitution therapies (IRTs) have the potential to induce long-term or even permanent drug-free remission in people with multiple sclerosis (MS). These therapies deplete components of the immune system with the aim of allowing the immune system to renew itself. Haematopoietic stem cell transplantation, the oral formulation cladribine and the monoclonal antibodies alemtuzumab, rituximab and ocrelizumab are frequently categorized as IRTs. However, the evidence that IRTs indeed renew adaptive immune cell repertoires and rebuild a healthy immune system in people with MS is variable. Instead, IRTs might foster the expansion of those cells that survive immunosuppression, and this expansion could be associated with acquisition of new functional phenotypes. Understanding immunological changes induced by IRTs and how they correlate with clinical outcomes will be instrumental in guiding the optimal use of immune reconstitution as a durable therapeutic strategy.